215 related articles for article (PubMed ID: 35592110)
1. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
Zhang S; Wang X; Gu H; Liu JQ
Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
Li Y; Sun Z; Sun W; Wang H; Zu J
Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Jiang HT; Li W; Zhang B; Gong Q; Qie HL
Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
Liu Y; Ge Q; Xu S; Li K; Liu Y
Front Oncol; 2022; 12():942678. PubMed ID: 36059654
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma.
Sun X; Xu J; Xie L; Guo W
Int J Gen Med; 2022; 15():7581-7591. PubMed ID: 36196372
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Sun L; Zhao Q; Wang Y; Wang Y; Zheng M; Ding X; Miao L
Int J Gen Med; 2023; 16():4165-4179. PubMed ID: 37720175
[TBL] [Abstract][Full Text] [Related]
8. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.
Li N; Wu T; Hong YG; Guo YZ; Cheng YF; Ma YJ; Bie LY; Cui DH; Gao XH; Tan BX; Li BS; Luo SX; Wang JS
BMC Med; 2022 Dec; 20(1):472. PubMed ID: 36482345
[TBL] [Abstract][Full Text] [Related]
9. The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma.
Song Y; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; He J; Huang J
Cancer Biol Med; 2021 Mar; 18(2):562-8. PubMed ID: 33724741
[TBL] [Abstract][Full Text] [Related]
10. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma].
Sun W; Zou X; Zhang W; Hu S; Ge K
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Feb; 41(2):250-255. PubMed ID: 33624599
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Gefitinib Plus Anlotinib for Patients with EGFR Positive Advanced Non-Small-Cell Lung Cancer: A Retrospective Exploratory Study.
Hu WX; Peng JC; Wang Y; Jin H; Geng N
Int J Gen Med; 2022; 15():4453-4464. PubMed ID: 35509604
[TBL] [Abstract][Full Text] [Related]
13. Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer.
Hao YY; Qiao YP; Cheng JD
Int J Gen Med; 2021; 14():10483-10493. PubMed ID: 35002304
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
Chen XQ; Zhao YX; Zhang CL; Wang XT; Zhang X; Chen X; Yuan CW; Zhao Q; Chen XJ
Drug Des Devel Ther; 2022; 16():1483-1493. PubMed ID: 35607597
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions.
Song PF; Xu N; Li Q
Cancer Manag Res; 2020; 12():11133-11143. PubMed ID: 33173346
[TBL] [Abstract][Full Text] [Related]
17. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
18. Implication of
Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
[No Abstract] [Full Text] [Related]
19. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
20. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.
Wang G; Beeraka NM; Xiao W; Zhang Y; Xue N; Chen G; Liu J; Liu Y
Technol Cancer Res Treat; 2022; 21():15330338221080939. PubMed ID: 35235470
[No Abstract] [Full Text] [Related]
[Next] [New Search]